See the DrugPatentWatch profile for kerendia
Kerendia (finerenone) is not designed to lower blood sugar levels. Its primary function is to reduce the risk of kidney disease progression and cardiovascular events in adults with chronic kidney disease (CKD) associated with type 2 diabetes [1][2].
How does Kerendia work for kidney disease?
Kerendia works by blocking the overactivation of the mineralocorticoid receptor (MR). This overactivation is linked to inflammation and fibrosis in the kidneys and heart, which can worsen kidney disease and cardiovascular issues in individuals with type 2 diabetes [2][3]. By inhibiting this pathway, Kerendia aims to reduce these damaging processes [2].
What are the key benefits of Kerendia?
Clinical studies have shown that Kerendia significantly reduces the risk of kidney disease progression, including a decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, and kidney-related death. It also lowers the risk of cardiovascular death, non-fatal heart attack, and heart failure hospitalization in the specified patient population [1][2].
When does Kerendia patent expire?
Information on specific patent expiry dates for Kerendia is available through specialized patent tracking services. DrugPatentWatch.com provides detailed data on drug patents, including expiry timelines, which can help determine when generic competition might become possible [4].
What are the side effects of Kerendia?
Common side effects associated with Kerendia include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [1][2]. Regular monitoring of potassium levels and blood pressure is recommended during treatment [2].
How does Kerendia compare to other diabetes medications?
Unlike many traditional diabetes medications that focus on blood glucose control, Kerendia targets the underlying mechanisms of kidney and heart damage in CKD associated with type 2 diabetes. While maintaining good blood sugar control is important for managing diabetes, Kerendia offers a complementary approach by addressing inflammation and fibrosis [2][3].
Sources:
[1] https://www.kerendia.com/
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-kerendia-finerenone-reduce-risk-kidney-disease-progression-and-cardiovascular-events
[3] https://www.bayer.com/en/news/press-releases/bayer-announces-us-fda-approval-kerendia-finerenone-reduce-risk-kidney-disease-progression-and-cardiovascular-events
[4] https://drugpatentwatch.com/